Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 11
- Registration Number
- NCT00985374
Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
Phase 2
Completed
- Conditions
- HCV Infection
- Interventions
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT00978497
- Locations
- 🇺🇸
United States, New York, New York, New York, United States
🇺🇸United States, Maryland, Lutherville, Maryland, United States
🇺🇸United States, California 2, San Clemente, California, United States
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 225
- Registration Number
- NCT00976989
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Phase 3
Completed
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 361
- Registration Number
- NCT00976911
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇩🇪Klinikum Nord Frauenklinik, Nürnberg, Germany
🇧🇪UZ Antwerpen, Edegem, Belgium
A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis
Phase 2
Terminated
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT00977379
TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: placebo
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 103
- Registration Number
- NCT00977106
A Study of RO5036505 in Patients With Moderate to Severe Asthma
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00967590
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma
Phase 2
Completed
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT00967330
A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
Phase 2
Withdrawn
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00964704
A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT00965653
© Copyright 2025. All Rights Reserved by MedPath